{Secret Stock Trends Revealed} Stay Ahead Before the Public Catch On

Included also in this email, is how Wall Street is preparing for a US government debt default. Find out how we can also prepare! Sponsored [ACT NOW: These Are The Top Profitable Stocks of 2023]( The stock market is currently in a volatile state, and uncertainty is rampant. However, there is no reason to panic. In fact, now is the ideal time to purchase stocks.[Go HERE to see the Potential Investing Opportunity]( By clicking the link you are subscribing to the Summa Money Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy [Privacy Policy/Disclosures](  Be Among the First to Seize Lucrative Opportunities in These Up and Coming Trends [Image]  Hello Stock Traders  Today we have something hotter than a ghost pepper — the world of biotech. You see, just like a batch of sourdough, it's rapidly fermenting, evolving, and brimming with bubbles of newness. These fresh industry trends are so cutting-edge that only a handful of folks are privy to them. I'm talking about blustering headwinds, enabling technologies, and the promise (or threat!) of disruption in the decade ahead. Now, if you're an investor, you'd want to be among those 'in the know', right? Well, here are three piping-hot trends currently cooking up a storm in the biotech kitchen. Firstly, let's chat about artificial intelligence. AI is expected to change the world, and biotech is definitely on its dance card. We've been slow-dancing with machine learning in drug discovery and screening for years, but it seems we're about to quicken the tempo. Big biopharma is keen on this AI rave, but they prefer to have a rehearsal with smaller businesses before going full swing. Cue the entry of companies like Schrödinger and Recursion Pharmaceuticals. They're like the techno DJs at this AI party, leading with their drug discovery and target screening platforms. This alliance offers the big players numerous boons like cost savings, speedier drug development, and lower failure rates. Pretty neat, huh? But here's a note of caution - the AI rave might be the talk of the town, but let's not be blinded by the strobe lights. Potential benefits and actual benefits are currently enjoying a long-distance relationship. Don't empty your piggy banks just yet because of AI's star-studded allure. Second on the menu, we have fresh forms of collaborations. They're shaking things up quite like a smoothie maker in drug discovery. Picture this - 23andMe is like a gold miner sitting on a mountain of consumer genetic data, thanks to their mail-order DNA testing business. They're ready to play Santa, gifting this valuable data to other biotechs to speed up their processes and cut costs. With access to the genetic info of more than 13.6 million people, collaborators are like kids in a candy store. And believe me, this is a candy most companies can't even dream of producing. Also, taking the stage are cost-cutting collaborations, led by the talented Ginkgo Bioworks. Picture them as a wish-granting genie for genetically modified organisms. But, let's temper our excitement. These cost-cutting maestros still need to prove their magic trick's authenticity and viability in the long-term. Last but certainly not least, we've got a trend that's as welcome as a skunk at a lawn party — the soaring costs of drug development. With more advanced tech and fewer easy wins, the R&D bills for biopharma players are shooting up like a homesick angel. In 2018, each approved drug cost about $1.7 billion. Fast forward to 2022, and you're looking at a whopping $2.6 billion! It's clear that new biotechs will have to dig deep into their pockets to play this game. The collaborations we discussed sound promising to mitigate these costs, but their impact on the industry is still as visible as a chameleon in a bag of Skittles. Remember to put on your skeptical glasses while evaluating any claims of cost-saving or quick-turnaround drug development. These three biotech trends are as new and uncharted as they come. Stay tuned, stay savvy, and stay ready to adapt. After all, just like in most things in life, the only constant is the thrill of the new.   Trade safe!  -James  Coming Up Next: The heavy hitters in the investment world are betting on AI. Want to know their bets? Find out in the article below!   SPONSORED 🔽 Sponsored [Fed’s Shocking New Plan to Control Your Money]( The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as July. This is a lot more than printing trillions of dollars or manipulating interest rates. It’s about every checking account, every purchase and every money transfer in America — including yours and mine.  [Click here to discover how to protect your money]( [Privacy Policy/Disclosures]( Safeguarding Against a US Debt Default: Wall Street's Strategies So here's the skinny: Uncle Sam has run up a pretty big tab – a staggering $31.4 trillion and counting – and the decision to increase the limit on this fiscal black hole is becoming a nail-biter for Wall Street. Oh, we've been here before, of course – most recently back in September 2021. But now, time is running out faster than a speeding bullet, and there's a collective jitteriness in the banking world that makes a long-tailed cat in a room full of rocking chairs look calm. We're now in the two-minute warning before the Treasury's June 1 deadline, after which we could be staring at an uncomfortable reality: the U.S. Government may not be able to pay all its debts. U.S. Treasury Secretary Janet Yellen has sounded the alarm bells loud and clear, but Wall Street bigwigs like Citigroup CEO Jane Fraser and JPMorgan Chase & CO CEO Jamie Dimon are, understandably, a little more than concerned. Now, you might be wondering: what would happen if the U.S. defaulted? Well, let's just say it wouldn't be pretty. U.S. government bonds are like the bedrock of the global financial system. So if Uncle Sam defaults, expect a financial earthquake that could cause shockwaves of volatility in equity, debt, and other markets. Trading Treasury positions would become as challenging as herding cats. Wall Street gurus warn that a Treasury market hiccup would ricochet across the derivative, mortgage, and commodity markets. Simply put, investors would start questioning the credibility of Treasuries used as collateral, much like doubting the authenticity of a three-dollar bill. Fearing such a financial tsunami, banks, brokers, and trading platforms are running drills and playing out scenarios like a coach prepping for the Super Bowl. This prep work includes game-planning for Treasury payments, gauging reactions of funding markets, ensuring they're armed to the teeth with tech, staff, and cash to handle high trading volumes, and assessing potential impacts on client contracts. Leading industry group, SIFMA, is also running through scenarios. Their playbook reads like a choose-your-own-adventure novel, with scenarios ranging from the Treasury rolling over maturing securities day-by-day, to the most disruptive scenario where the Treasury fails to pay both principal and coupon and does not extend maturities. Each twist in the plot could lead to significant operational hiccups and need for daily manual adjustments in trading and settlement processes. According to Rob Toomey, SIFMA's managing director, they're just trying to help their members navigate through what could be a highly disruptive situation. I mean, it's like trying to predict the twists and turns of an unexplored jungle – no easy feat! And let's not forget the Treasury Market Practices Group and the Depository Trust & Clearing Corporation, each with their own game plan. They've drawn up blueprints for trading in unpaid Treasuries, akin to running an obstacle course in uncharted territory. In the end, the financial world is akin to a band of explorers charting the vast, unknown sea of potential U.S. default. It's an unprecedented, rough, and uncharted course, but rest assured, every possible scenario is being considered, every strategy evaluated, and every precaution taken. They're determined to sail through the storm, even if it means navigating the treacherous, uncharted waters of a debt ceiling crisis. But as investors, the best thing we can do now, is be prepared in as many eventualities as possible.   Disclaimer:  The material in this document is for informational purposes based on our proprietary research. It is not an offering, specific recommendation, or a solicitation of an offer to buy or sell any securities mentioned or discussed herein.  Any performance results discussed herein represent past performance, are not a guarantee of future performance, and are not indicative of any specific investment.  Due to the timing of information presented, any investment performance reflected within this document may be adjusted after the publication and distribution of this material. There can be no assurance that the future performance of any specific investment, investment strategy, or product made reference to directly or indirectly in this communication will be profitable, be equal to any corresponding indicated historical performance levels or be suitable for your portfolio.  Any investment results set forth in this document are not net of expenses and execution costs, nor do they account for other relevant trading or investment fees. Please visit tradersontrend.com/terms for our full Terms and Conditions.  COE MEDIA.   1126 S Federal Hwy Unit #827   Fort Lauderdale, FL 33316 [UnsubscribeÂ](  [Privacy Policy](